Trial Profile
Efficacy and safety of treatment with new ARB Azilsartan in hypertension patients who did not show target blood pressure by other ARBs
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Mar 2022
Price :
$35
*
At a glance
- Drugs Azilsartan (Primary)
- Indications Hypertension
- Focus Therapeutic Use
- 08 Mar 2022 Status changed from recruiting to completed.
- 01 Sep 2012 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.
- 22 Aug 2012 New trial record